Analyst firms · Wolfe Research · ABBV
Wolfe Research ABBV price target and rating history
AbbVie Inc. (ABBV) · Health Care
Wolfe Research rates AbbVie Inc. (ABBV) Outperform with a $300 price target, as of its latest action on Aug 13, 2026. It has published 4 rating actions on ABBV since February 2023, including 1 upgrade and 2 downgrades. Across 8 firms with a ABBV price target in the last 12 months, the median target is $263.50. Wolfe Research's $300 is 14% above that.
- Current rating
- Outperform
- Price target
- $300
- Median target, all firms
- $263.50
- Actions on ABBV
- 4
Wolfe Research price target on ABBV
Every Wolfe Research rating on ABBV
- Aug 13, 2026
- Jan 8, 2026
- Nov 15, 2024
- Feb 22, 2023
How other firms rate ABBV
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $300 | Aug 13, 2026 |
| Erste Group | Buy | Aug 5, 2026 | |
| BofA Securities | Buy | $234 | Apr 30, 2026 |
| Canaccord Genuity | Buy | $262 | Apr 21, 2026 |
| RBC Capital Markets | Outperform | $260 | Feb 25, 2026 |
| Barclays | Overweight | $275 | Feb 20, 2026 |
| UBS | Neutral | $240 | Jan 7, 2026 |
| HSBC | Buy | $265 | Dec 10, 2025 |
| Scotiabank | Sector Outperform | $280 | Nov 13, 2025 |
Questions about Wolfe Research and ABBV
- What is Wolfe Research's price target for ABBV?
- Wolfe Research's latest stated price target for AbbVie Inc. (ABBV) is $300, from its action on Aug 13, 2026.
- What is Wolfe Research's rating on ABBV?
- Wolfe Research rates ABBV Outperform, a bullish rating, as of Aug 13, 2026.
- When did Wolfe Research last change its view on ABBV?
- On Aug 13, 2026, Wolfe Research upgrades to Outperform from Peer Perform, price target $300.
- How does Wolfe Research's ABBV target compare with other analysts?
- Across 8 firms with a ABBV price target in the last 12 months, the median target is $263.50. Wolfe Research's $300 is 14% above that.
More ABBV rating histories
All Wolfe Research ratingsABBV news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.